MegaGen has launched the ARi (AnyRidge Incisor) implant system, a fourth-generation design engineered specifically for severely atrophic anterior ridges. By achieving primary stability directly from unresorbed basal bone, this new implant can often eliminate the need for guided bone regeneration (GBR).
What's new
The ARi system tackles one of implantology's most demanding clinical scenarios: placing implants in the anterior maxilla complicated by advanced ridge atrophy. Traditionally, this requires preliminary bone augmentation through GBR. That means extra surgical interventions, extended treatment times, and higher costs for the patient.
MegaGen's core innovation lies in a design that actively engages dense basal cortical bone instead of relying on the compromised alveolar ridge. Consequently, the implant secures high primary stability even in narrow zones where conventional fixtures would demand prior volume restoration.
Technically, the fixture features a 10-degree external conical hex connection to ensure joint stability, alongside a soft tissue-friendly surface optimized to lower the risk of peri-implantitis. MegaGen positions ARi as a solution that frequently eliminates the need for augmentation. Ultimately, the treating clinician must still decide whether GBR is necessary based on the patient's unique anatomy.
Technical specs
| Parameter | MegaGen ARi |
|---|---|
| Generation | 4th-generation AnyRidge |
| Connection | 10° external conical hex |
| Primary indication | Anterior atrophic ridges |
| Primary stability | From basal cortical bone |
| Surface | Soft tissue-optimised |
| Augmentation | Often unnecessary (clinical decision) |
| Prosthetic compatibility | AnyRidge component system |
| Clinical evidence | Peer-reviewed study, MDPI Dentistry Journal |
Market context
Founded in 2002 by a group of more than 70 dentists, MegaGen stands as South Korea's leading implant manufacturer and its largest exporter to the European market. The AnyRidge family remains the company's flagship product line, building its reputation on a distinctive knife-thread design that consistently delivers high primary stability.
While clinically significant, the narrow-ridge implant segment remains a niche market. Clinicians traditionally rely on alternative approaches like narrow-diameter implants (such as the 2.9 mm Straumann Roxolid), ridge splitting techniques, or conventional GBR using membranes and bone grafts. ARi introduces a fundamentally different philosophy. Rather than rebuilding lost bone, it utilizes the bone that remains in the deeper layers.
A peer-reviewed study published in the MDPI Dentistry Journal details the clinical application of the ARi system in severely atrophic cases, offering early scientific validation. Naturally, a comprehensive clinical assessment will require larger, long-term studies.
Professionals can view the ARi system firsthand at Dentex Brussels from 1-3 October 2026, which will serve as a major European showcase for the product.
Relevance for CEE region
MegaGen already operates a well-developed distribution network across Poland and the broader CEE region. Polish implantologists frequently choose standard AnyRidge implants for their reliable quality and competitive pricing. The introduction of ARi expands this portfolio, offering a direct solution for cases that previously demanded costly augmentation.
For local clinics that regularly treat patients with advanced bone atrophy—especially within the growing senior demographic—ARi could shave several months and an entire surgical procedure off standard treatment plans. This translates to substantial economic value for both the practice and the patient.
The system should hit the Polish market in the second half of 2026. MegaGen has not yet confirmed official pricing.
FAQ
What is MegaGen ARi? ARi (AnyRidge Incisor) is a fourth-generation AnyRidge implant engineered specifically for atrophic anterior ridges. It secures stability directly from basal cortical bone, frequently bypassing the need for prior GBR augmentation.
How does ARi differ from standard AnyRidge? MegaGen optimized ARi specifically for narrow anterior ridges suffering from advanced atrophy. It utilizes basal bone for stabilization, whereas the standard AnyRidge addresses a much broader range of indications within alveolar bone.
Does ARi completely eliminate the need for bone augmentation? Not always. While the manufacturer states that ARi "often" eliminates the need for GBR, the final clinical decision still depends entirely on the individual patient's anatomy.